GlassScriptPhysician profile
David M Holtzman
NPI 1972521789
$164,847.49
in general payments reported to CMS, 2019-2025
11 companies · $65K in 2025
The $65K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,832 · 2020: $11K · 2021: $26K · 2023: $26K · 2024: $32K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $2,827 · Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,344.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,900.00 |
| Travel and Lodging | $2,827.28 |
| Food and Beverage | $106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $62,268.58 | 2019-2025 | |
| Genentech USA, INC. | $49,150.91 | 2023-2024 | |
| C2n Diagnostics, LLC | $40,000.00 | 2025 | Precivityad2 |
| Pfizer INC. | $3,900.00 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $2,060.00 | 2023-2024 | |
| F. Hoffmann-La Roche Ag | $1,960.00 | 2024 | |
| Biogen, INC. | $1,839.00 | 2023 | |
| Abbvie INC. | $1,787.86 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,275.00 | 2021 | |
| Merck Sharp & Dohme LLC | $562.50 | 2020 | |
| Stryker Corporation | $43.64 | 2024 | Actishield Cf, Actishield |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,000,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Holtzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.